Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Type x diabetes

October 10th 2016

Resulting from the loss of pancreatic Beta cells, type 1 diabetes has traditionally been considered a diagnosis affecting children and adolescents. However, it is increasingly apparent that it can occur at any age. Indeed, the 2015 NICE guidelines advice is not to discount a diagnosis of type 1 diabetes if an adult presents with a BMI of 25 and above or is aged 50 years or above. Topically, the new prime minister is a good example of such an atypical presentation. There is usually a desire both from the patient and health care professional to determine the type of diabetes at presentation with the increasing use of auto antibodies to aid the diagnosis. Islet Cell Antibodies (ICA, against cytoplasmic proteins in the beta cell), antibodies to Glutamic Acid Decarboxylase (GAD-65), Insulin Auto antibodies (IAA), and IA-2A, to protein tyrosine phosphatase are often measured at diagnosis (GAD and PICA being the most common). Auto antibodies against GAD 65 are found in 80% of newly diagnosed patients with type 1 diabetes at clinical presentation whilst the presence of ICA and IA-2A at diagnosis for type 1 diabetes range from 69-90% and 54-75%, respectively. IAA prevalence correlates inversely with age at onset of diabetes and is usually the first marker in young children at risk for diabetes being found in approximately 70% at time of diagnosis. However, NICE advises routinely against testing for these antibodies apart unless the presentation has unusual features such as age and BMI>25 with the caveat that antibody tests have their lowest false negative rate at the time of diagnosis, and that the false negative rate rises thereafter. Overall, whilst antibody testing has its place, clinical impression and the priority to keep the patient safe from ketosis (which may require early use of insulin) should take priority over an early decision about diabetes sub type which usually becomes obvious with time.

Dr Mark Freeman

Categories: Updates

Diabetes Updates Archive

calendar-iconDiabetes Updates Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Napp DiabetesBoehringer IngelheimNovo NordiskAstraZeneca

Silver Sponsors

About Ascensia Diabetes CareAbbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership